- Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110–121. doi: 10.1038/nrgastro.2016.181.
- Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscle Thromb Vasc Biol. 2007;27(11):2276–2283. doi: 10.1161/ATVBAHA.107.147835.
- Qin B, Yang M, Fu H, et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose response meta-analysis. Arthritis Res Ther. 2015;17:86. doi: 10.1186/s13075-015-0601-x.
- Uko V, Vortia E, Achkar JP, et al. Impact of abdominal visceral adipose tissue on disease outcomes in pediatric Crohn’s disease. Inflamm Bowel Dis. 2014;20(12):2286–2291. doi: 10.1097/MIB.0000000000000200.
- Zulian A, Cancello R, Micheletto G, et al. Visceral adipocytes: old actors in obesity and new protagonists in Crohn’s disease? Gut. 2012;61(1):86–94. doi: 10.1136/gutjnl-2011-300391.
- Long MD, Crandall WV, Leibowitz IH, et al. The prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(10):2162–2168. doi: 10.1002/ibd.21585.
- Hu Q, Ren J, Li G, Wu X, Li J. The impact of obesity on the clinical course of inflammatory bowel disease: a meta-analysis. Med Sci Monit. 2017;23:2599–2606. doi: 10.12659/MSM.901969.
- Worthington JJ. The intestinal immunoendocrine axis: novel cross talk between enteroendocrine cells and the immune system during infection and inflammatory bowel disease. Biochem Soc Trans. 2015;43(4):727–733. doi: 10.1042/BST20150090.
- Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.
- Seminerio JL, Koutroubakis IE, Ramos-Rivers C, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(12):2857–2863. doi: 10.1053/j.gastro.2011.10.001.
- Pringle PL, Stewart KO, Peloquin JM, et al. Body mass index, genetic susceptibility and risk of complications among individuals with Crohn’s disease. Inflamm Bowel Dis. 2015;21(10):2304–2310. doi: 10.1097/MIB.0000000000000498.
- Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(10):2118–2124. doi: 10.1097/MIB.0b013e31829cf401.
- Poon SS, Asher R, Jackson R, et al. Body mass index and smoking affect thioguanine bucleotide levels in inflammatory bowel disease. J Crohns Colitis. 2015;9(8):640–646. doi: 10.1093/ecco-jcc/jjv084.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 32, 2019 - Issue 1
Original Articles
Effects of obesity on the course of inflammatory bowel disease
, MD, 
, & , MD
Umair MasoodDepartment of Gastroenterology, State University of New York Upstate Medical University, Syracuse, New York; Correspondence[email protected]
http://orcid.org/0000-0002-1170-405X
, MD http://orcid.org/0000-0002-1170-405X, Scott MinchenbergCollege of Medicine, State University of New York Upstate Medical University, Syracuse, New Yorkhttp://orcid.org/0000-0002-0445-5956
, BS http://orcid.org/0000-0002-0445-5956 & , MD